Eli Lilly and Company, a leading pharmaceutical firm, announced on June 5, 2024, that Anat Ashkenazi has resigned from her position as Chief Financial Officer (CFO) to pursue a new career opportunity outside of the pharmaceutical industry. Ashkenazi, who has been with Eli Lilly for 23 years, will continue her duties and remain a member of the Executive Committee until July 2024. During her tenure as CFO, the company experienced significant growth and established a foundation for future success. Prior to her role as CFO, Ashkenazi held various financial leadership positions within the company, including senior vice president and controller of Lilly Research Laboratories. Eli Lilly has commenced both internal and external searches to find Ashkenazi's successor. The announcement was made through a press release attached as Exhibit 99.1 to the company's Current Report on Form 8-K filed with the SEC.

Eli Lilly and Company, a leading pharmaceutical firm, announced on June 5, 2024, that Anat Ashkenazi has resigned from her position as Chief Financial Officer (CFO) to pursue a new career opportunity outside of the pharmaceutical industry. Ashkenazi, who has been with Eli Lilly for 23 years, will continue her duties and remain a member of the Executive Committee until July 2024. During her tenure as CFO, the company experienced significant growth and established a foundation for future success. Prior to her role as CFO, Ashkenazi held various financial leadership positions within the company, including senior vice president and controller of Lilly Research Laboratories. Eli Lilly has commenced both internal and external searches to find Ashkenazi's successor. The announcement was made through a press release attached as Exhibit 99.1 to the company's Current Report on Form 8-K filed with the SEC.